Mauro Adolfo G, Bonaventura Aldo, Vecchié Alessandra, Mezzaroma Eleonora, Carbone Salvatore, Narayan Pratyush, Potere Nicola, Cannatà Antonio, Paolini John F, Bussani Rossana, Montecucco Fabrizio, Sinagra Gianfranco, Van Tassel Benjamin W, Abbate Antonio, Toldo Stefano
Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Johnson Research Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
JACC Basic Transl Sci. 2021 Feb 22;6(2):137-150. doi: 10.1016/j.jacbts.2020.11.016. eCollection 2021 Feb.
Human samples of patients with chronic pericarditis and appropriate control subjects were stained for the inflammasome components. A mouse model of pericarditis was developed through the intrapericardial injection of zymosan A. Different inflammasome blockers were tested in the mouse model. Patients with pericarditis presented an intensification of the inflammasome activation compared with control subjects. The experimental model showed the pathological features of pericarditis. Among inflammasome blockers, NLRP3 inflammasome inhibitor, anakinra, and interleukin-1 trap were found to significantly improve pericardial alterations. Colchicine partially improved the pericardial inflammation. An intense activation of the inflammasome in pericarditis was demonstrated both in humans and in mice.
对慢性心包炎患者的人体样本和合适的对照受试者进行炎性小体成分染色。通过心包内注射酵母聚糖A建立心包炎小鼠模型。在该小鼠模型中测试了不同的炎性小体阻滞剂。与对照受试者相比，心包炎患者的炎性小体激活增强。实验模型显示了心包炎的病理特征。在炎性小体阻滞剂中，发现NLRP3炎性小体抑制剂、阿那白滞素和白细胞介素-1陷阱能显著改善心包改变。秋水仙碱部分改善了心包炎症。在人和小鼠中均证实了心包炎中炎性小体的强烈激活。
Zotero 插件
